Takeda's Dengue Vaccine Still Promising, But Could Be A Niche Market

Long-term Phase II data have backed Takeda's drive to study its dengue vaccine in Phase III, but to grow the market the company may have to reverse the reluctance of countries to fund public vaccination campaigns.